Edited for not offending:
I can wait for a Christmas
Edited for not offending:
I can wait for a Christmas present to show itself this year. Nader said... approval possible by end of year. Which will be first? Covid or HIV? I am good with that race. I am also good with if he is a month off due to whatever reason that could come up. Some complainers just blow me away. Like they could jump in and run this company better. If that’s who you are?
We didn’t have the best news we expected today. But it was more news that de-risks our investment in my opinion. The things I liked...
Trial continues with no major modification! That’s huge! Slight added mod of 42 days to improve our strength in the next interim look. I am good with this help. De-risking!
Looks like HIV in U.K.,EU and Canada is going to be submitted soon. Like a week for U.K. and the next week for Canada. This is great news... yet we hear complaining? Whining? Really? More de-risking.
I am happy to hear our updates on other indications and to see our focus is moving forward in all that matters to the investor. MTNBC, Basket Trial (BTD?), GVHD, Nash and long haulers. I hope these are not slowed and continue to further the bottom line of this company. I am excited still to see just how many indications will get approved. That’s why I will stay in this investment.
Covid is a possible big time revenue depending on how we can ramp up our supply chain. That’s the bottle neck we have. Solve that problem and look out on the revenue front. I am a firm believer we won’t have a long term vaccine. Sad about it but reality is this Covid Coronavirus mutates like HIV. Not encouraging.
Ask Gilead what they thought they could make on Covid. There are just another domino that just fell in the wrong direction. Opens up a pretty big market for a drug that works and we know we do. Just need the p value to show it. It’s a numbers game and we have a small budget in comparison to others but somehow on our beer budget we will be popping champagne bottles. Just imagine that. Our time is coming in many ways. If you were here for just Covid. You haven’t done enough D&D and should know the over 60 possible indications this inflammation controller/ autoimmune regulator will be approved for. Yet we have reasons to complain... like I said before. The complainers can leave and you won’t be missed... that’s a guarantee. Time is still on our side. We are still in the lead for first approval in severe/critical. But that doesn’t really matter first or second. There will be lots of revenue for whomever is in the approval club when all is said and done.
Now the whiners can pick apart my positive post... will it make me sell shares? Nope...
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
New Leadership to Drive Expansion In a boost to its commitment to scaling up, Castillo Engineering, based in Maitland, Florida, has roped in two veterans from the renewables sector as vice presidents. Aaron Carrillo and Devin Radovich, who share a history of successful collaboration at Renewable Energy Systems Americas (RES), are set to guide Castillo's growth in the...
Continue Reading
Just when you think you've seen it all in the world of craftsmanship, along comes a dynamo like Spencer Peterman. For over 25 years, he's been turning what others discard into treasures. Fallen trees? Most folks see firewood. Spencer sees a future masterpiece. And now, he’s rolling out the welcome mat for his loyal customers with a special sale that runs until December...
Continue Reading
Celebrating Boardroom Mavericks at NACD Gala September 2026 has brought some sparkling recognition to the elites guiding today's corporate governance landscapes. The National Association of Corporate Directors (NACD) has announced their Directorship 100 honorees, tipping their hats to stellar individuals firing on all cylinders in the boardroom. Who's Getting the Nod?...
Continue Reading
Big Insights in the AI World of 2026 Well folks, if there's one thing making waves in the boardrooms this year, it's AI. Dresner Advisory Services just threw down a gauntlet for companies with their fresh batch of reports focused on the dizzying world of AI. They ripped right into it, exploring how firms can bag a heap of benefits and deal with the hurdles that come with...
Continue Reading
Breaking New Ground in Cancer Immunotherapy Today feels like a pivotal day for Anixa Biosciences. Their announcement about securing a patent in Australia for their trailblazing breast cancer vaccine is like planting a flag on new, promising territory. This is no minor step; it's a strategic leap for the company as it strengthens its intellectual grip on the global...
Continue Reading
Every once in a while, a piece of tech comes along that makes you sit up and say, ‘Now that’s a game-changer!’ And with the recent rave reviews, Tenera Care seems to hit just that sweet spot for folks in the senior living game. By handing Dublin Glenn Memory Care the gold in the KISS category at the 2026 McKnight's Technology Awards, it’s clear the industry is...
Continue Reading
Trouble Brews at Electrical Consultants, Inc. Right on the heels of a long workday, some employees of Electrical Consultants, Inc. seem to be getting a double whammy. The company is tangled up in a class action lawsuit lodged by the well-known Blumenthal Nordrehaug Bhowmik De Blouw LLP. This ain't your everyday grievance, folks; we're talking meal and rest period...
Continue Reading
Game-Changer for AI Data Centers? Across the tech landscape, space is a premium, and Molex's new VersaBeam Mini arrives like a hail Mary in the fourth quarter. In AI data centers, squeezing down every single component counts—especially when optical density's in play. What we're seeing here is a potential paradigm shift. A 3x density improvement from a tiny 3.5 x 9 mm...
Continue Reading
Breaking New Ground in Arlington and Baltimore Deepening their stake in the Capital Region's future, HNTB has thrown open new office doors in Arlington, Virginia, and Baltimore, Maryland. We're not just talking fancy buildings, folks—this is about securing a piece of the infrastructure pie that's only going to get bigger and tastier. Infrastructure's the backbone of...
Continue Reading
New PostalAnnex Location Opens in Bastrop, TX Here's a fresh chapter in the books for Annex Brands, Inc. They've just cut the ribbon on a brand spanking new PostalAnnex in Bastrop, Texas, handing the reins over to eager fresh faces, Chetan Modi and Karan Desai. And you know what? This ain't just any regular location. It's a one-stop-shop for anything you could need, from...
Continue Reading
Top 5 Most Recently Viewed Articles
IMF Recommendations on Federal Reserve Easing The International Monetary Fund (IMF) has recently made a notable statement regarding the monetary policy of the U.S. Federal Reserve. During a scheduled news briefing, IMF spokesperson Julie Kozack mentioned that now is the right time for the Federal Reserve to think about starting a process of monetary easing, given the...
Continue Reading
DraftKings Inc. Achieves Record Revenue in Q2 DraftKings Inc. announced remarkable financial results for the second quarter, showcasing a significant leap in its performance. This includes a record revenue of $1.51 billion, representing a 37% increase year-over-year. This impressive growth surpassed analyst expectations, as the consensus estimate was only $1.39 billion....
Continue Reading
Lassila & Tikanoja Responds to Financial Challenges in Sweden Lassila & Tikanoja Plc has recently announced a significant measure in response to the ongoing challenges faced in their Swedish facility services business. In an upcoming quarterly report, the company will recognize impairments and make provisions totaling approximately EUR 28 million, which will be documented...
Continue Reading
National Grid's Performance Overview In its latest pre-close update covering the six months up to September 30, National Grid (NYSE: NGG) (LON: NG) announced that the group's performance aligns with expectations, highlighting that the underlying earnings per share (EPS) are anticipated to be predominantly driven in the latter half of the fiscal year. Citi's Revised...
Continue Reading
High Science App: A New Era for Cannabis Fans The High Science app has officially launched, becoming a pivotal resource for the cannabis community. This application serves as a central hub where fans can connect, engage, and stay informed about the fascinating world of cannabis. From accessing episodes of the popular High Science TV series to discovering the latest...
Continue Reading